Wednesday, March 30, 2016

BRIEF-Actinium Pharmaceuticals receives orphan drug designation from FDA for Iomab-B

* Receives orphan drug designation from FDA for Iomab-B in

treating refractory and relapsed acute myeloid leukemia in

elderly patients

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)